Alexander's, Inc. — News

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.02 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to FFO of $2.88 per share a year ago.

zacks.com - 2026-08-03 10:41:23

PARAMUS, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2026 today and reported:

globenewswire.com - 2026-08-03 09:09:00

PARAMUS, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 28, 2026 to stockholders of record on August 10, 2026.

globenewswire.com - 2026-07-29 13:01:00

PARAMUS, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 3, 2026, before the New York Stock Exchange opens.

globenewswire.com - 2026-07-21 12:23:00

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com - 2026-06-30 16:40:00

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.

globenewswire.com - 2026-06-30 08:00:00

PARAMUS, N. J. , June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.

globenewswire.com - 2026-06-29 17:22:19

PARAMUS, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.

globenewswire.com - 2026-06-29 17:22:00

VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | OTC: GXPLF | FRA: HW3), is pleased to announce that the Company has fulfilled all the obligations of its property option agreement (the “Agreement”) to earn a 100% legal and beneficial interest in the Carpenter Lake Uranium Project (“Carpenter Lake” or the “Project”), located on the southern margin of the Athabasca Basin in northern Saskatchewan, Canada. Greenridge entered into the Agreement in May 2024 with ALX Resources Corp. (“ALX”) and Renegade Gold Inc. (“Renegade” and together with ALX, the “Optionors”) and has since carried out systematic exploration at the Project, including diamond drilling, in 2024, 2025 and 2026.

globenewswire.com - 2026-06-16 08:00:00

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.

globenewswire.com - 2026-06-01 08:00:00

PARAMUS, N. J. , May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc. The gross sales price was $235.

globenewswire.com - 2026-05-28 16:54:39

PARAMUS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc.

globenewswire.com - 2026-05-28 16:54:00

Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!

forbes.com - 2026-05-17 11:00:10

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.

marketbeat.com - 2026-05-08 16:07:19

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

globenewswire.com - 2026-05-08 08:00:00

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

globenewswire.com - 2026-05-07 08:00:00

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.6 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $4.06 per share a year ago.

zacks.com - 2026-05-04 10:46:19